DK2313106T3 - Medicinsk anvendelse af radikalbinderen og antioxidanten alfa-1-mikroglobulin - Google Patents
Medicinsk anvendelse af radikalbinderen og antioxidanten alfa-1-mikroglobulin Download PDFInfo
- Publication number
- DK2313106T3 DK2313106T3 DK09777272.7T DK09777272T DK2313106T3 DK 2313106 T3 DK2313106 T3 DK 2313106T3 DK 09777272 T DK09777272 T DK 09777272T DK 2313106 T3 DK2313106 T3 DK 2313106T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- microglobulin
- alpha
- heme
- haemoglobin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
Claims (10)
1
1. Alfa-1 -mikroglobulin til anvendelse til behandling eller profylakse af en sygdom eller tilstand, som involverer oxidativ stress, ved reparation eller forebyggelse af oxidativ skade ved hjælp af en kombination af enzymatisk reduktion, ikke-enzymatisk reduktion og radikalbinding, med det forbehold, at sygdommen eller tilstanden ikke er præeklampsi.
2. Alfa-1-mikroglobulin til anvendelse ifølge krav 1, hvor sygdommen eller tilstanden er forbundet med tilstedeværelse af frit hæmoglobin i en kropsvæske.
3. Alfa-1-mikroglobulin ifølge krav 1 eller 2, som udviser mindst 60% identitet med humant alfa-1-mikroglobulin (SEQ NO: 1).
4. Alfa-1-mikroglobulin til anvendelse ifølge et hvilket som helst af de foregående krav, hvor alfa-1-mikroglobulinet er humant alfa-1-mikroglobulin (SEQ NO: 1).
5. Alfa-1-mikroglobulin til anvendelse ifølge et hvilket som helst af kravene 1-2, hvor alfa-1-mikroglobulinet udviser mindst 60% identitet med humant rekombinant alfa-1-mikroglobulin (SEQ NO: 2).
6. Alfa-1-mikroglobulin til anvendelse ifølge et hvilket som helst af kravene 1-2, 5, hvor alfa-1-mikroglobulinet er humant rekombinant alfa-1-mikroglobulin (SEQ ID NO: 2).
7. Alfa-1-mikroglobulin til anvendelse ifølge et hvilket som helst af kravene 1-6, hvor alfa-1-mikroglobulinet administreres parenteralt.
8. Alfa-1-mikroglobulin til anvendelse ifølge et hvilket som helst af kravene 1-6, hvor alfa-1-mikroglobulinet administreres lokalt, f.eks. til et kropshulrum eller på huden. 2
9. Alfa-1-mikroglobulin til anvendelse ifølge et hvilket som helst af de foregående krav, hvor alfa-1-mikroglobulinet administreres i form af en sammensætning, som omfatter alfa-1-mikroglobulin og en farmaceutisk acceptabel excipiens.
10. Alfa-1-mikroglobulin til anvendelse ifølge krav 9, hvor den farmaceutisk acceptable excipiens er valgt blandt opløsningsmidler, pH-justeringsmidler, osmotisk aktive midler, co-opløsningsmidler, solubiliseringsmidler, emulgatorer, opslæmningsmidler, overfladeaktive midler, befugtningsmidler osv.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13533808P | 2008-07-18 | 2008-07-18 | |
| DKPA200801024 | 2008-07-18 | ||
| US18938108P | 2008-08-18 | 2008-08-18 | |
| DKPA200801116 | 2008-08-18 | ||
| US19750608P | 2008-10-27 | 2008-10-27 | |
| DKPA200801478 | 2008-10-27 | ||
| PCT/EP2009/005217 WO2010006809A2 (en) | 2008-07-18 | 2009-07-17 | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2313106T3 true DK2313106T3 (da) | 2016-07-25 |
Family
ID=41550762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09777272.7T DK2313106T3 (da) | 2008-07-18 | 2009-07-17 | Medicinsk anvendelse af radikalbinderen og antioxidanten alfa-1-mikroglobulin |
| DK13172049.2T DK2638915T3 (da) | 2008-07-18 | 2009-07-17 | Medicinsk anvendelse af radikalbinderen og antioxidanten alfa-1-mikroglobulin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13172049.2T DK2638915T3 (da) | 2008-07-18 | 2009-07-17 | Medicinsk anvendelse af radikalbinderen og antioxidanten alfa-1-mikroglobulin |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10350268B2 (da) |
| EP (2) | EP2638915B1 (da) |
| JP (3) | JP5694928B2 (da) |
| AU (1) | AU2009270435B2 (da) |
| CA (1) | CA2730531A1 (da) |
| DK (2) | DK2313106T3 (da) |
| ES (2) | ES2571956T3 (da) |
| HR (2) | HRP20160760T1 (da) |
| HU (2) | HUE027953T2 (da) |
| PL (2) | PL2313106T3 (da) |
| PT (1) | PT2638915T (da) |
| WO (1) | WO2010006809A2 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3087991A1 (en) | 2003-11-08 | 2016-11-02 | Prothera Biologics | Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| JP5604111B2 (ja) | 2007-02-12 | 2014-10-08 | エー１エム ファーマ エービー | 子癇前症の診断及び治療 |
| BRPI0913949A2 (pt) | 2008-05-28 | 2015-10-20 | Pro Thera Biolog Llc | preparação e composição de proteínas inibidoras inter-alfa a partir de sangue |
| DK2900254T3 (da) * | 2012-09-05 | 2016-08-29 | A1M Pharma Ab | Alfa-1-mikroglobulin til anvendelse ved behandlingen af mitokondrie-relaterede sygdomme |
| WO2014039987A2 (en) * | 2012-09-09 | 2014-03-13 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
| WO2015095553A1 (en) | 2013-12-20 | 2015-06-25 | Nephrogenesis, Llc | Methods and apparatus for kidney dialysis |
| CA3017836A1 (en) * | 2016-03-18 | 2017-09-21 | A1M Pharma Ab | Novel alpha-1-microglobulin derived proteins and their use |
| US20190314449A1 (en) * | 2016-11-16 | 2019-10-17 | The Board Of Regents Of The University Of Texas System | Cyclic dipeptides and wound healing |
| EP3703729A1 (en) * | 2017-11-03 | 2020-09-09 | Guard Therapeutics International AB | Use of alpha-1-microglobulin for protection of bone marrow cells |
| JP6906807B2 (ja) * | 2018-08-31 | 2021-07-21 | 一般社団法人クラインシュタイン医工学パースペクティブ | 透析装置 |
| WO2024165674A1 (en) | 2023-02-08 | 2024-08-15 | Guard Therapeutics International AB | Alpha-1-microglobulin derived peptide fragments and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166133A (en) * | 1991-04-17 | 1992-11-24 | Cetus Corporation | Method for inhibing adhesion of white blood cells to endothelial cells |
| US6103691A (en) * | 1994-03-23 | 2000-08-15 | Tschesche; Harald | Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins |
| US5910482A (en) | 1996-03-19 | 1999-06-08 | Board Of Regents, The University Of Texas System | Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor |
| JP2001348342A (ja) | 2001-04-12 | 2001-12-18 | Nippon Zoki Pharmaceut Co Ltd | 免疫調整・抗炎症剤 |
| DE10125883A1 (de) * | 2001-05-28 | 2002-12-12 | Serumwerk Bernburg Ag | Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie |
| DE10237423A1 (de) * | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
| US20070060512A1 (en) * | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
| AR045074A1 (es) | 2003-07-23 | 2005-10-12 | Applied Research Systems | Uso de cd164 soluble en desordenes inflamatorios y autoinmunes |
| ITMI20032528A1 (it) | 2003-12-19 | 2005-06-20 | Francesco Santangelo | Uso di cistina o di cisteina per la prevenzione e il |
| US20060105419A1 (en) | 2004-08-16 | 2006-05-18 | Biosite, Inc. | Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions |
| JP2007001922A (ja) | 2005-06-23 | 2007-01-11 | Asahi Kasei Pharma Kk | 透析患者における腎疾患改善剤、又は機能性食品 |
| US20070292421A1 (en) | 2005-07-28 | 2007-12-20 | Feinberg Bruce B | Method for treating preeclampsia |
| US20080133141A1 (en) | 2005-12-22 | 2008-06-05 | Frost Stephen J | Weighted Scoring Methods and Use Thereof in Screening |
| JP5604111B2 (ja) * | 2007-02-12 | 2014-10-08 | エー１エム ファーマ エービー | 子癇前症の診断及び治療 |
-
2009
- 2009-07-17 HU HUE09777272A patent/HUE027953T2/en unknown
- 2009-07-17 EP EP13172049.2A patent/EP2638915B1/en not_active Not-in-force
- 2009-07-17 HU HUE13172049A patent/HUE030274T2/en unknown
- 2009-07-17 EP EP09777272.7A patent/EP2313106B1/en active Active
- 2009-07-17 PT PT131720492T patent/PT2638915T/pt unknown
- 2009-07-17 PL PL09777272T patent/PL2313106T3/pl unknown
- 2009-07-17 ES ES09777272T patent/ES2571956T3/es active Active
- 2009-07-17 CA CA2730531A patent/CA2730531A1/en not_active Abandoned
- 2009-07-17 AU AU2009270435A patent/AU2009270435B2/en not_active Ceased
- 2009-07-17 DK DK09777272.7T patent/DK2313106T3/da active
- 2009-07-17 PL PL13172049T patent/PL2638915T3/pl unknown
- 2009-07-17 ES ES13172049.2T patent/ES2614490T3/es active Active
- 2009-07-17 JP JP2011517819A patent/JP5694928B2/ja not_active Expired - Fee Related
- 2009-07-17 US US13/054,188 patent/US10350268B2/en active Active
- 2009-07-17 WO PCT/EP2009/005217 patent/WO2010006809A2/en active Application Filing
- 2009-07-17 DK DK13172049.2T patent/DK2638915T3/da active
-
2014
- 2014-11-21 JP JP2014236500A patent/JP6406987B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-10 JP JP2015241096A patent/JP6175478B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-29 HR HRP20160760TT patent/HRP20160760T1/hr unknown
- 2016-12-29 HR HRP20161808TT patent/HRP20161808T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010006809A3 (en) | 2010-05-27 |
| HRP20161808T1 (hr) | 2017-02-24 |
| HRP20160760T1 (hr) | 2016-08-12 |
| ES2571956T3 (es) | 2016-05-27 |
| AU2009270435B2 (en) | 2014-10-16 |
| EP2313106B1 (en) | 2016-03-30 |
| ES2614490T3 (es) | 2017-05-31 |
| PT2638915T (pt) | 2017-01-10 |
| EP2638915A1 (en) | 2013-09-18 |
| WO2010006809A2 (en) | 2010-01-21 |
| US10350268B2 (en) | 2019-07-16 |
| JP2016102125A (ja) | 2016-06-02 |
| JP5694928B2 (ja) | 2015-04-01 |
| PL2638915T3 (pl) | 2017-04-28 |
| JP6406987B2 (ja) | 2018-10-17 |
| PL2313106T3 (pl) | 2016-08-31 |
| EP2638915B1 (en) | 2016-10-19 |
| HUE030274T2 (en) | 2017-05-29 |
| CA2730531A1 (en) | 2010-01-21 |
| JP2012505154A (ja) | 2012-03-01 |
| HUE027953T2 (en) | 2017-01-30 |
| AU2009270435A1 (en) | 2010-01-21 |
| US20110190208A1 (en) | 2011-08-04 |
| DK2638915T3 (da) | 2017-01-30 |
| JP2015071620A (ja) | 2015-04-16 |
| JP6175478B2 (ja) | 2017-08-02 |
| EP2313106A2 (en) | 2011-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2313106T3 (da) | Medicinsk anvendelse af radikalbinderen og antioxidanten alfa-1-mikroglobulin | |
| Olsson et al. | Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for α1-microglobulin | |
| JP2018203756A (ja) | ミトコンドリア関連疾患の治療に使用するためのα−１−ミクログロブリン | |
| JP5685773B2 (ja) | 血管新生および創傷治癒活性がある薬剤 | |
| KR20090033329A (ko) | 가교된 헤모글로빈 혈액 대용품을 사용한 급성 혈액 손실 빈혈의 치료 방법 | |
| CA2879019A1 (en) | Glutathione-elevating compositions and uses thereof | |
| AU2014262273B2 (en) | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin | |
| JP2022533365A (ja) | 出血性脳卒中後の有害な二次神経学的転帰を処置する際に使用するためのハプトグロビン | |
| Kumar et al. | A novel peptide derivative exhibits antiinflammatory and antioxidant activity in adjuvant induced arthritis in rats | |
| McCormick et al. | Clinically applicable thermal preconditioning attenuates leukocyte–endothelial interactions | |
| RU2405558C2 (ru) | Лекарственный препарат для лечения гипоксических и токсических митохондриальных нарушений и способ его получения | |
| RU2747121C1 (ru) | Способ применения средства на основе модифицированного пероксиредоксина 2 человека для коррекции последствий ишемически-реперфузионного поражения почек | |
| Televiak et al. | Dynamic of indices of lipid peroxidation and antioxidant protection in muscular tissue and blood serum of rats with acute ischemia-reperfusion | |
| Çekmez et al. | Comparing beneficial effects of inhaled nitric oxide to L-arginine in necrotizing enterocolitis model in neonatal rats | |
| Dobryszycka | Haptoglobin in the new millenium | |
| Powanda | Polyhemoglobin-superoxide dismutase-catalase blood substitute for ischemia-reperfusion in brain | |
| KR20180116385A (ko) | 조영제의 사용과 관련하여 신장 보호에서 이용하기 위한 알파-1-마이크로글로불린 | |
| Arvapalli | Deferasirox decreases age-associated iron accumulation in the aging F344BN rat heart | |
| BRAIN | Science of Physiology | |
| WO2014205077A1 (en) | Hemoglobin compositions |